PAK1 Rabbit Polyclonal Antibody

CAT#: AP14801PU-N

PAK1 rabbit polyclonal antibody, Aff - Purified



Need it in bulk or conjugated?
Get a free quote

CNY 6,160.00


货期*
5周

规格
    • 400 ul

Product images

Specifications

Product Data
Applications IHC, WB
Recommend Dilution ELISA: 1/1,000.
Western blotting: 1/50 - 1/100.
Immunohistochemistry: 1/10 - 1/50.
Reactivity Human
Host Rabbit
Clonality Polyclonal
Immunogen This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide corresponding to amino acid residues surrounding T423 of human PAK1.
Specificity This antibody reacts to PAK1.
Formulation PBS with 0.09% (W/V) sodium azide
State: Aff - Purified
State: Liquid purified Ig
Concentration lot specific
Purification Protein A column, followed by peptide affinity purification
Conjugation Unconjugated
Storage Condition Store the antibody undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer.
Avoid repeated freezing and thawing.
Gene Name p21 (RAC1) activated kinase 1
Background PAK1, a member of the STE20 subfamily of Ser/Thr protein kinases, acts on a variety of targets. It is likely to be the GTPase effector that links the Rho-related GTPases to the JNK MAP kinase pathway. Activity is inhibited in cells undergoing apoptosis, potentially due to binding of CDC2L1 and CDC2L2. The protein interacts tightly with GTP-bound but not GDP-bound CDC42/P21 and RAC1. PAK1 binds to the caspase-cleaved p110 isoform of CDC2L1 and CDC2L2, p110C, but not the full-length proteins. It is a component of cytoplasmic complexes, which also contain PXN, ARHGEF6 and GIT1. The protein is autophosphorylated when activated by CDC42/p21. Structurally, the PAK1 contains 1 CRIB domain.
Synonyms PAK 1, PAK-1, Alpha-PAK, PAK alpha, p21-activated kinase 1, p65-PAK
Reference Data
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.
Customer Reviews 
Loading...